Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (111-120 of 418) with videos related to

Pageof 42
Sort By:
Cancer Causes & Control : CCC|September 27, 2005
A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States)Keith T Flaherty, Charles S Fuchs, Graham A Colditz, et al.
The Oncologist|April 16, 2021
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyCaroline A Nebhan, Douglas B Johnson, Ryan J Sullivan, et al.
Journal of Neuro-Oncology|February 18, 2018
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicityRifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, et al.
Cancer|April 4, 2003
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancerKeith T Flaherty, James P Stevenson, Maryann Gallagher, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2011
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohortLu Si, Yan Kong, Xiaowei Xu, et al.
Cancer Biology & Therapy|January 27, 2016
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitorsPhilip Eliades, David M Miller, Benchun Miao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenibLucia Jilaveanu, Christopher Zito, Sandra J Lee, et al.
Archives of Dermatology|March 21, 2012
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanomaAllireza Alloo, Lilit Garibyan, Nicole LeBoeuf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
Human Pathology|December 17, 2009
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysJanice M Mehnert, Mary M McCarthy, Lucia Jilaveanu, et al.
Pageof 42

Showing results (111-120 of 418) with videos related to

Sort By:
Pageof 42
Cancer Causes & Control : CCC|September 27, 2005
A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States)Keith T Flaherty, Charles S Fuchs, Graham A Colditz, et al.
The Oncologist|April 16, 2021
Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II StudyCaroline A Nebhan, Douglas B Johnson, Ryan J Sullivan, et al.
Journal of Neuro-Oncology|February 18, 2018
The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicityRifaquat Rahman, Alfonso Cortes, Andrzej Niemierko, et al.
Cancer|April 4, 2003
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancerKeith T Flaherty, James P Stevenson, Maryann Gallagher, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2011
Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohortLu Si, Yan Kong, Xiaowei Xu, et al.
Cancer Biology & Therapy|January 27, 2016
A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitorsPhilip Eliades, David M Miller, Benchun Miao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenibLucia Jilaveanu, Christopher Zito, Sandra J Lee, et al.
Archives of Dermatology|March 21, 2012
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanomaAllireza Alloo, Lilit Garibyan, Nicole LeBoeuf, et al.
European Journal of Cancer (Oxford, England : 1990)|July 5, 2021
Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancersDirk Schadendorf, Caroline Robert, Reinhard Dummer, et al.
Human Pathology|December 17, 2009
Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarraysJanice M Mehnert, Mary M McCarthy, Lucia Jilaveanu, et al.
Pageof 42